Current evidence supports CLDN18.2 as a candidate biomarker for biomarker-enriched investigation, not as an established therapeutic target in CMA, and proposes a framework centered on lineage reprogramming, antigen enrichment, assay standardization, and therapeutic translation.
Wei Yu, Sheng-Tian Wei, Shi-Qing Wan et al.· Frontiers in Pharmacology· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies, with a dismal prognosis and a 5-year overall survival rate of 5–10%. Owing to the absence of specific symptoms at early stages, the majority of patients are first diagnosed with already locally advanced or metastatic disease. Cons...